Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Acute dyskinetic syndrome during chloropromazine treatment of a female patient with CYP2D6 poor metabolism phenotype].

Psychiatria polska - 1 Jan 2000

Beszłej Jan Aleksander, Grzesiak Magdalena, Milejski Piotr

Abstract excerpt

The authors describe the case of a female patient with the diagnosis of schizophrenia and the CYP2D6 poor metaboliser phenotype (PM phenotype), who experienced severe extrapyramidal side effects, including acute dystonia, while being treated with chloropromazine at 100 mg per day (in the third da...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP2D6
Share to Dyskinesia, Drug-Induced

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Schizophrenia

Share to Treatment Outcome

Source

Identifiers

PMID: 18046980

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18046980-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Acute dyskinetic syndrome during chloropromazine treatment of a female patient with CYP2D6 poor metabolism phenotype].PMID 18046980Read ↗

[Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].Semantic proximity Read ↗

[Pharmaco-resistance and side effects of antipsychotics associated with poor metabolizer phenotype for cytochrome P450 2D6 in a context of early-onset schizophrenia: A case report].Semantic proximity Read ↗

Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency.Semantic proximity Read ↗

[Clinical pharmacogenetics in the treatment of schizophrenia].Semantic proximity Read ↗

[Clinical pharmacogenetics in the treatment of schizophrenia].Semantic proximity Read ↗

[CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy].Semantic proximity Read ↗

[Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].Semantic proximity Read ↗

The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.Semantic proximity Read ↗

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.Semantic proximity Read ↗

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.Semantic proximity Read ↗

[Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology].Semantic proximity Read ↗

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.